- Home
- VCEL
VCEL
Vericel Corporation
as 01-17-2025 4:00pm EST
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.8B | IPO Year: | 1997 |
| Target Price: | $62.29 | AVG Volume (30 days): | 424.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.69 - $61.49 | Next Earning Date: | 02-27-2025 |
| Revenue: | $226,844,000 | Revenue Growth: | 22.48% |
| Revenue Growth (this year): | 23.82% | Revenue Growth (next year): | 22.51% |
Stock Insider Trading Activity of Vericel Corporation (VCEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wotton Paul K | VCEL | Director | Dec 4 '24 | Sell | $58.72 | 2,600 | $152,672.00 | 27,402 | |
| Hopper Jonathan Mark | VCEL | Chief Medical Officer | Dec 2 '24 | Sell | $58.72 | 10,000 | $587,200.00 | 58,371 | |
| ZERBE ROBERT L MD | VCEL | Director | Nov 22 '24 | Sell | $60.00 | 2,500 | $150,000.00 | 26,595 | |
| Colangelo Dominick | VCEL | President and CEO | Nov 13 '24 | Sell | $54.75 | 35,000 | $1,916,250.00 | 220,937 | |
| MCLAUGHLIN KEVIN F | VCEL | Director | Nov 13 '24 | Sell | $55.54 | 7,000 | $388,780.00 | 11,900 | |
| ZERBE ROBERT L MD | VCEL | Director | Nov 11 '24 | Sell | $56.25 | 5,000 | $281,250.00 | 26,595 |
Latest Vericel Corporation News
VCEL Breaking Stock News: Dive into VCEL Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
VCEL: Raising target price to $62.00
MT Newswires
4 days ago
Vericel Reports Q4 Preliminary Unaudited Revenue -- Shares Fall
GlobeNewswire
4 days ago
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
Simply Wall St.
5 days ago
High Growth Tech Stocks To Watch In January 2025
GlobeNewswire
11 days ago
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
Argus Research
a month ago
VCEL: What does Argus have to say about VCEL?
TipRanks
a month ago
Vericel price target raised to $67 from $61 at Truist
MT Newswires
a month ago
Truist Securities Raises Price Target on Vericel to $67 From $61, Keeps Buy Rating
Compare VCEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCEL Vericel Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.